Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH(R) for the Treatment of Common Warts
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH(R) for the Treatment of Common Warts GlobeNewswire July 01, 2025 – Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule […]